JobsOhio Ventures — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Clarametyx develops novel immune-enabling therapeutics targeting bacterial biofilms to modify disease progression in patients with chronic respiratory diseases.
BiotechHealthtechMedical DevicesColumbus, US
David Richards(Executive Officer)Peter G. Kleinhenz(Director)Michael Layman(Director)Chuck Bramlage(Director)Larry Edwards(Director)Michael Triplett II(Director)
Co-investorsCincyTechOhio Innovation FundRev1 Ventures
Myoptechs develops treatments and interventions for myopia, a progressive eye disease that causes worsening distance vision and can lead to sight-threatening complications.
HealthtechMedical DevicesColumbus, US
Paul Grimm(Executive Officer, Director)inBrad Beasecker(Executive Officer)in
BoardWayne Embree(Director)Robin Sears(Director)in
Co-investorsRev1 Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.